Combating Tuberculosis (TB) is still a tough challenge as TB stands as the number one infectious disease killer and leading contributor to antimicrobial resistance. Exacerbated patient non-adherence to TB medications due to long treatment timelines, harsh side effects, and poor regimen adherence has led to an increase in drug-resistant TB (DR-TB). TB patients with comorbidities like HIV/AIDS are particularly at risk of dying from TB. Despite the extensive global initiatives and the introduction of newer treatment options such as Bedaquiline and Petromanid, emerging and increasing drug-resistant TB (DR-TB) remains a major hurdle to global TB control efforts. Recovery rates are alarmingly low, with nearly 68% for multidrug-resistant Tuberculosis (MDR-TB) and only 30% for extensively drug-resistant Tuberculosis (XDR-TB), underscoring its severity. Updating our understanding of TB and its drug resistance mechanisms is crucial for developing effective strategies and innovative treatments. This book, therefore, focuses on the emergence of resistance in Mycobacterium tuberculosis (M. tuberculosis) strains, the challenges associated with DR-TB, current therapeutic targets, and the novel chemical classes and regimens within the existing TB drug development pipeline.
Jetzt kaufen
- Arbeit zitieren
- Swapna Ponnampalli (Autor:in), 2025, Targeting Resistance. Reinforcing the TB Drug Pipeline with Innovative Small Molecules, München, GRIN Verlag, https://www.grin.com/document/1665332
